Abstract

BackgroundAccurate differentiation between malignant and benign changes in soft tissue and bone lesions is essential for the prevention of unnecessary biopsies and surgical resection. Nevertheless, it remains a challenge and a standard diagnosis modality is urgently needed. The objective of this study was to evaluate the usefulness of 18F-fluorodeoxyglucose (18F-FDG) PET/CT-derived parameters to differentiate soft tissue sarcoma (STS) and bone sarcoma (BS) from benign lesions.MethodsPatients who had undergone pre-treatment 18F-FDG PET/CT imaging and subsequent pathological diagnoses to confirm malignant (STS and BS, n = 37) and benign (n = 33) soft tissue and bone lesions were retrospectively reviewed. The tumor size, PET and low-dose CT visual characteristics, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneous factor (HF) of each lesion were measured. Univariate and multivariate logistic regression analyses were conducted to determine the significant risk factors to distinguish sarcoma from benign lesions. To establish a regression model based on independent risk factors, and the receiver operating characteristic curves (ROCs) of individual parameters and their combination were plotted and compared. Conventional imaging scans were re-analyzed, and the diagnostic performance compared with the regression model.ResultsUnivariate analysis results revealed that tumor size, SUVmax, MTV, TLG, and HF of 18F-FDG PET/CT imaging in the STS and BS group were all higher than in the benign lesions group (all P values were < 0.01). The differences in the visual characteristics between the two groups were also all statistically significant (P < 0.05). However, the multivariate regression model only included SUVmax and HF as independent risk factors, for which the odds ratios were 1.135 (95%CI: 1.026 ~ 1.256, P = 0.014) and 7.869 (95%CI: 2.119 ~ 29.230, P = 0.002), respectively. The regression model was constructed using the following expression: Logit (P) = − 2.461 + 0.127SUVmax + 2.063HF. The area under the ROC was 0.860, which was higher than SUVmax (0.744) and HF (0.790). The diagnostic performance of the regression model was superior to those of individual parameters and conventional imaging.ConclusionThe regression model including SUVmax and HF based on 18F-FDG PET/CT imaging may be useful for differentiating STS and BS from benign lesions.

Highlights

  • Accurate differentiation between malignant and benign changes in soft tissue and bone lesions is essential for the prevention of unnecessary biopsies and surgical resection

  • The univariate analysis results showed that the tumor size, Maximum standardized uptake value (SUVmax) (12.4 ± 9 vs. 7 ± 5.2, P < 0.001), metabolic tumor volume (MTV) (57.7 ± 54.9 vs. 18.8 ± 16.5, P < 0.05), total lesion glycolysis (TLG) (26.3 ± 513.8 vs. 81.1 ± 119.8, P < 0.001), and heterogeneous factor (HF) (1.39 ± 1.31 vs. 0.38 ± 0.35, P < 0.001) in the soft tissue sarcoma (STS) and bone sarcoma (BS) group were all significantly higher than in the benign lesions group

  • Based on multivariate logistic regression analysis, only SUVmax and HF were identified as independent risk factors for malignant tumors, and could be incorporated into the logistic regression predictive model

Read more

Summary

Introduction

Accurate differentiation between malignant and benign changes in soft tissue and bone lesions is essential for the prevention of unnecessary biopsies and surgical resection. It remains a challenge and a standard diagnosis modality is urgently needed. Accurate discrimination between malignant and benign soft tissue and bone tumors is essential for the prevention of unnecessary pathological biopsies and unplanned surgical resections. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is a molecular imaging technique widely utilized to noninvasively quantify the glycolytic metabolism of tumors in vivo It is typically employed during clinical assessment for tumor detection, staging and efficacy evaluation as well as prognosis prediction [6,7,8]. Numerous studies show that HF is closely related to the therapeutic response and prognosis of malignant tumors [11,12,13], discrimination between malignant and benign soft tissue and bone tumors utilizing this parameter remains unexplored

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call